MedTrace Logo

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

NCT05862194 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 534

Last updated 2023-08-22

No results posted yet for this study

Summary

This retrospective, external comparator study for Lazertinib aims to assess the real-world effectiveness of Lazertinib as the second-line treatment versus platinum-based chemotherapy in patients with epidermal growth receptor sensitizing mutation-positive, locally advanced or metastatic Non-small Lung cancer.

Conditions

Interventions

DRUG

Lazertinib

Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period

DRUG

Platinum-based Chemotherapy

Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-01
Primary Completion
2022-04-30
Completion
2023-03-20
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05862194 on ClinicalTrials.gov